Cargando…

Ependyma: a new target for autoantibodies in neuromyelitis optica?

Neuromyelitis optica (NMO) is an autoimmune demyelinating disease of the central nervous system characterized by the presence of autoantibodies (called NMO-IgG) targeting aquaporin-4. Aquaporin-4 is expressed at the perivascular foot processes of astrocytes, in the glia limitans, but also at the epe...

Descripción completa

Detalles Bibliográficos
Autores principales: Bigotte, Maxime, Gimenez, Marie, Gavoille, Antoine, Deligiannopoulou, Adamantia, El Hajj, Aseel, Croze, Severine, Goumaidi, Abdelghafar, Malleret, Gael, Salin, Paul, Giraudon, Pascale, Ruiz, Anne, Marignier, Romain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897195/
https://www.ncbi.nlm.nih.gov/pubmed/36751497
http://dx.doi.org/10.1093/braincomms/fcac307
_version_ 1784882201675956224
author Bigotte, Maxime
Gimenez, Marie
Gavoille, Antoine
Deligiannopoulou, Adamantia
El Hajj, Aseel
Croze, Severine
Goumaidi, Abdelghafar
Malleret, Gael
Salin, Paul
Giraudon, Pascale
Ruiz, Anne
Marignier, Romain
author_facet Bigotte, Maxime
Gimenez, Marie
Gavoille, Antoine
Deligiannopoulou, Adamantia
El Hajj, Aseel
Croze, Severine
Goumaidi, Abdelghafar
Malleret, Gael
Salin, Paul
Giraudon, Pascale
Ruiz, Anne
Marignier, Romain
author_sort Bigotte, Maxime
collection PubMed
description Neuromyelitis optica (NMO) is an autoimmune demyelinating disease of the central nervous system characterized by the presence of autoantibodies (called NMO-IgG) targeting aquaporin-4. Aquaporin-4 is expressed at the perivascular foot processes of astrocytes, in the glia limitans, but also at the ependyma. Most studies have focused on studying the pathogenicity of NMO-IgG on astrocytes, and NMO is now considered an astrocytopathy. However, periependymal lesions are observed in NMO suggesting that ependymal cells could also be targeted by NMO-IgG. Ependymal cells regulate CSF-parenchyma molecular exchanges and CSF flow, and are a niche for sub-ventricular neural stem cells. Our aim was to examine the effect of antibodies from NMO patients on ependymal cells. We exposed two models, i.e. primary cultures of rat ependymal cells and explant cultures of rat lateral ventricular wall whole mounts, to purified IgG of NMO patients (NMO-IgG) for 24 hours. We then evaluated the treatment effect using immunolabelling, functional assays, ependymal flow analysis and bulk RNA sequencing. For each experiment, the effects were compared with those of purified IgG from a healthy donors and non-treated cells. We found that: (i) NMO-IgG induced aquaporin-4 agglomeration at the surface of ependymal cells and induced cell enlargement in comparison to controls. In parallel, it induced an increase in gap junction connexin-43 plaque size; (ii) NMO-IgG altered the orientation of ciliary basal bodies and functionally impaired cilia motility; (iii) NMO-IgG activated the proliferation of sub-ventricular neural stem cells; (iv) treatment with NMO-IgG up-regulated the expression of pro-inflammatory cytokines and chemokines in the transcriptomic analysis. Our study showed that NMO-IgG can trigger an early and specific reactive phenotype in ependymal cells, with functional alterations of intercellular communication and cilia, activation of sub-ventricular stem cell proliferation and the secretion of pro-inflammatory cytokines. These findings suggest a key role for ependymal cells in the early phase of NMO lesion formation.
format Online
Article
Text
id pubmed-9897195
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-98971952023-02-06 Ependyma: a new target for autoantibodies in neuromyelitis optica? Bigotte, Maxime Gimenez, Marie Gavoille, Antoine Deligiannopoulou, Adamantia El Hajj, Aseel Croze, Severine Goumaidi, Abdelghafar Malleret, Gael Salin, Paul Giraudon, Pascale Ruiz, Anne Marignier, Romain Brain Commun Original Article Neuromyelitis optica (NMO) is an autoimmune demyelinating disease of the central nervous system characterized by the presence of autoantibodies (called NMO-IgG) targeting aquaporin-4. Aquaporin-4 is expressed at the perivascular foot processes of astrocytes, in the glia limitans, but also at the ependyma. Most studies have focused on studying the pathogenicity of NMO-IgG on astrocytes, and NMO is now considered an astrocytopathy. However, periependymal lesions are observed in NMO suggesting that ependymal cells could also be targeted by NMO-IgG. Ependymal cells regulate CSF-parenchyma molecular exchanges and CSF flow, and are a niche for sub-ventricular neural stem cells. Our aim was to examine the effect of antibodies from NMO patients on ependymal cells. We exposed two models, i.e. primary cultures of rat ependymal cells and explant cultures of rat lateral ventricular wall whole mounts, to purified IgG of NMO patients (NMO-IgG) for 24 hours. We then evaluated the treatment effect using immunolabelling, functional assays, ependymal flow analysis and bulk RNA sequencing. For each experiment, the effects were compared with those of purified IgG from a healthy donors and non-treated cells. We found that: (i) NMO-IgG induced aquaporin-4 agglomeration at the surface of ependymal cells and induced cell enlargement in comparison to controls. In parallel, it induced an increase in gap junction connexin-43 plaque size; (ii) NMO-IgG altered the orientation of ciliary basal bodies and functionally impaired cilia motility; (iii) NMO-IgG activated the proliferation of sub-ventricular neural stem cells; (iv) treatment with NMO-IgG up-regulated the expression of pro-inflammatory cytokines and chemokines in the transcriptomic analysis. Our study showed that NMO-IgG can trigger an early and specific reactive phenotype in ependymal cells, with functional alterations of intercellular communication and cilia, activation of sub-ventricular stem cell proliferation and the secretion of pro-inflammatory cytokines. These findings suggest a key role for ependymal cells in the early phase of NMO lesion formation. Oxford University Press 2022-11-30 /pmc/articles/PMC9897195/ /pubmed/36751497 http://dx.doi.org/10.1093/braincomms/fcac307 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Bigotte, Maxime
Gimenez, Marie
Gavoille, Antoine
Deligiannopoulou, Adamantia
El Hajj, Aseel
Croze, Severine
Goumaidi, Abdelghafar
Malleret, Gael
Salin, Paul
Giraudon, Pascale
Ruiz, Anne
Marignier, Romain
Ependyma: a new target for autoantibodies in neuromyelitis optica?
title Ependyma: a new target for autoantibodies in neuromyelitis optica?
title_full Ependyma: a new target for autoantibodies in neuromyelitis optica?
title_fullStr Ependyma: a new target for autoantibodies in neuromyelitis optica?
title_full_unstemmed Ependyma: a new target for autoantibodies in neuromyelitis optica?
title_short Ependyma: a new target for autoantibodies in neuromyelitis optica?
title_sort ependyma: a new target for autoantibodies in neuromyelitis optica?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897195/
https://www.ncbi.nlm.nih.gov/pubmed/36751497
http://dx.doi.org/10.1093/braincomms/fcac307
work_keys_str_mv AT bigottemaxime ependymaanewtargetforautoantibodiesinneuromyelitisoptica
AT gimenezmarie ependymaanewtargetforautoantibodiesinneuromyelitisoptica
AT gavoilleantoine ependymaanewtargetforautoantibodiesinneuromyelitisoptica
AT deligiannopoulouadamantia ependymaanewtargetforautoantibodiesinneuromyelitisoptica
AT elhajjaseel ependymaanewtargetforautoantibodiesinneuromyelitisoptica
AT crozeseverine ependymaanewtargetforautoantibodiesinneuromyelitisoptica
AT goumaidiabdelghafar ependymaanewtargetforautoantibodiesinneuromyelitisoptica
AT malleretgael ependymaanewtargetforautoantibodiesinneuromyelitisoptica
AT salinpaul ependymaanewtargetforautoantibodiesinneuromyelitisoptica
AT giraudonpascale ependymaanewtargetforautoantibodiesinneuromyelitisoptica
AT ruizanne ependymaanewtargetforautoantibodiesinneuromyelitisoptica
AT marignierromain ependymaanewtargetforautoantibodiesinneuromyelitisoptica